Johnson & Johnson (NYSE:JNJ) Shares Acquired by Main Line Retirement Advisors LLC

Main Line Retirement Advisors LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 5.3% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,525 shares of the company’s stock after buying an additional 77 shares during the quarter. Main Line Retirement Advisors LLC’s holdings in Johnson & Johnson were worth $241,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Kennedy Capital Management LLC grew its stake in shares of Johnson & Johnson by 18.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 20,478 shares of the company’s stock worth $3,189,000 after purchasing an additional 3,206 shares during the period. Rainsberger Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Rainsberger Wealth Advisors Inc. now owns 14,584 shares of the company’s stock worth $2,271,000 after purchasing an additional 373 shares during the period. Industrial Alliance Investment Management Inc. grew its stake in shares of Johnson & Johnson by 125.4% during the 3rd quarter. Industrial Alliance Investment Management Inc. now owns 6,671 shares of the company’s stock worth $1,039,000 after purchasing an additional 3,711 shares during the period. Annandale Capital LLC grew its stake in shares of Johnson & Johnson by 6.8% during the 3rd quarter. Annandale Capital LLC now owns 19,171 shares of the company’s stock worth $2,986,000 after purchasing an additional 1,221 shares during the period. Finally, Dana Investment Advisors Inc. grew its stake in shares of Johnson & Johnson by 125.4% during the 3rd quarter. Dana Investment Advisors Inc. now owns 106,403 shares of the company’s stock worth $16,572,000 after purchasing an additional 59,199 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $145.62 on Thursday. The firm has a market cap of $350.46 billion, a price-to-earnings ratio of 9.08, a price-to-earnings-growth ratio of 2.43 and a beta of 0.52. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The company’s 50-day moving average is $148.02 and its two-hundred day moving average is $153.91. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the company posted $2.68 EPS. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.62 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Bank of America decreased their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.